



**Shifting gear in antimicrobial and anticancer peptides
biophysical studies: From vesicles to cells**

Journal:	<i>Journal of Peptide Science</i>
Manuscript ID:	PSC-14-0228.R1
Wiley - Manuscript type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Freire, João; Instituto de Medicina Molecular, Physical Biochemistry Gaspar, Diana; Instituto de Medicina Molecular, Physical Biochemistry Veiga, Ana; Instituto de Medicina Molecular, Physical Biochemistry Castanho, Miguel; Faculdade de Medicina da Univ Lisboa, Instituto de Bioquimica
Keywords:	Cell, Vesicle, Peptide, Membrane, Biophysics, Spectroscopy, Antimicrobial, Anticancer

SCHOLARONE™
Manuscripts

1
2
3 **Shifting gear in antimicrobial and anticancer peptides biophysical studies:**
4 **From vesicles to cells****
5

6
7
8 João Freire, Diana Gaspar, A. Salomé Veiga, Miguel Castanho*
9

10
11 Instituto de Medicina Molecular,
12 Faculdade de Medicina,
13 Universidade de Lisboa
14 Av. Professor Egas Moniz
15 1649-028 Lisboa
16 Portugal

17 *) Correspondence: macastanho@medicina.ulisboa.pt
18
19
20
21

22 **Running title:** Shifting gear from vesicles to cells
23
24
25
26

27 **) Invited Article for the Anniversary Issue 2015 of Journal of Peptide Science.

28 The review is based on a part of the Zervas Award Lecture delivered by Prof. Miguel
29 Castanho at the 33rd European Peptide Symposium in Sofia, 31 August – 5 September,
30 Bulgaria 2014.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Despite the intensive study on the mechanism of action of membrane-active molecules such as antimicrobial and anticancer peptides, most of the biophysical work has been performed using artificial model systems, mainly lipid vesicles. The use of these systems allows full control of the experimental parameters and to obtain molecular-level detail on the action of peptides but the correlation with biological action is intangible. Recently several biophysical methodologies have been translated to studies using bacterial and cancer cells. Here we review biophysical studies on the mechanism of action of antimicrobial and anticancer peptides performed directly on cells. The data in these studies allow to correlate vesicle- and cell-based studies and fill the vesicle-cell interdisciplinary gap.

Keywords: Cell, Vesicle, Peptide, Membrane, Biophysics, Spectroscopy, Bacteria, Antimicrobial, Anticancer, Lipid

Abbreviations: SLM, supported lipid bilayers; BLM, black lipid membranes; AMPs, antimicrobial peptides; LPS, lipopolysaccharide; AFM, atomic force microscopy; CD, Circular Dichroism; LTA, lipoteichoic acids; NMR, nuclear magnetic resonance; MIC, minimum inhibitory concentration; FACS, fluorescence activated cell sorting; ACPs, anticancer peptides; CPPs, cell-penetrating peptides.

INTRODUCTION

Over the years biophysicists have studied intensively the mode of action of membrane-active molecules. The need for quantitative data has driven these researchers to use artificial systems, mainly vesicles, so that full control of the experimental parameters is achieved. Vesicles are made of artificial mixtures of lipids, which means that the researcher controls the fluidity, the thickness, the concentration, the charge, and the chemical nature of the lipids, as well as the presence, or absence, of sterols. Depending on the mode of preparation of vesicles, unilamellar systems of controlled size or multilamellar systems are obtained. Moreover, there are methods that enable loading vesicles with chemical species such ions and fluorophores.

One of the very few limitations in work with vesicles is the serious difficulty of preparing vesicles of asymmetrical lipid bilayers. In cases in which asymmetrical bilayers

1
2
3 are needed, biophysicists resort to planar lipid bilayers totally or partially supported such as
4 the SLM (Supported Lipid Bilayers) [1] or BLM (Black Lipid Membranes) [2], respectively.
5 Vesicles prepared directly from biological membranes may lose their organization and were
6 not generally adopted.
7
8

9
10 Vesicles and other artificial lipid bilayer systems enabled collecting massive amounts
11 of molecular-level detail data on the action of antimicrobial peptides (AMPs). A reasonably
12 well structured understanding of the molecular events implied in membrane perturbation and
13 disruption by AMPs has emerged. Most AMPs have high affinity for anionic lipid
14 membranes, change conformation upon contact with the lipids, and undergo critical events at
15 specific local peptide-to-lipid ratios. These critical events are typically a change in
16 orientation and/or oligomerization in the membrane [3], so they occur at high membrane
17 coverage by the peptides.
18
19
20
21
22

23 The details of AMP-induced membrane disruption in bacteria are rarely known and
24 the validity of extrapolating knowledge on AMP action in vesicles to bacteria is largely
25 elusive. Bridging the gap between microbiology and biophysics remains a challenge yet to
26 be met. Being up to the challenge is a matter of both biophysicists and microbiologists
27 leaving their reductionist **disciplinary approach engage** interdisciplinary work, not an
28 intrinsic limitation of the techniques and methodologies available to tackle the gap.
29
30
31
32

33 It is our purpose with this discussion paper to demonstrate that quantitative
34 biophysical studies of AMPs in bacteria are possible and important recent advances have
35 been achieved to elucidate the molecular events that take place at bacterial membranes, and
36 their (dis)similarities with their counterparts in vesicles.
37
38
39
40

41 **LIPID BILAYERS: SIMPLE BUT UBIQUITOUS**

42
43

44 Over millions of years of molecular, cellular, and species evolution, it is amazing that cell
45 membranes have converged, without exception, to lipid bilayer-based structures. The
46 chemical nature of the lipids varies, the presence of non-lipid molecules varies, charge and
47 fluidity vary, but lipid bilayers are the essence of any biological membrane. This makes lipid
48 bilayers the gold reference standard model for biological membranes. Biophysicists praise
49 their simplicity, microbiologists **undervalue them** but their importance is not ignored.
50
51
52

53 If AMPs accumulate in the bacterial membranes as in vesicles or not, if they change
54 conformation and supra-molecular organization as in vesicles or not, if they disrupt
55 membrane integrity as in vesicles or not, if they collapse bacteria as they collapse the
56
57
58
59
60

1
2
3 morphology of vesicles or not, *etc.* are matters of **vivid debate**. Discussions are fueled more
4 by intuition rather than objective evidence-based opinion. However, important yet dispersed,
5 data in the literature is frequently overlooked.
6
7

8 9 **BACTERIAL MEMBRANES: MORE THAN BILAYERS**

10
11
12 Bacterial membranes are complex (Figure 1) when compared to human cells for instance. In
13 Gram-negative bacteria the presence of a highly organized lipopolysaccharide (LPS) layer
14 constitutes a barrier difficult to mimic in artificial systems. In Gram-positive bacteria is not
15 possible to isolate the intact peptidoglycan wall and use it as single component of an
16 artificial system. Therefore, it is not possible to work with perfect mimics of LPS
17 membranes and peptidoglycan shells. This prevents researchers from working with isolated
18 lipid bilayers, isolated layers of LPS and isolated peptidoglycan meshes forming a closed
19 shell. It is thus impossible for biophysicists to extrapolate the biological action of AMPs
20 from the data obtained with realistic models of each membrane component. The only way
21 for biophysicists to unravel the biological action of AMPs is to apply their techniques
22 directly on bacteria, which demands adaptations and methodological refinement. Although
23 not trivial, successful adaptations have been reported for Atomic Force Microscopy (AFM),
24 Fluorescence Spectroscopy, Circular Dichroism (CD), Infrared Spectroscopy, among others
25 [4-7]. Some of these studies will be visited in the following sections.
26
27

28
29 Although there are no artificial systems that match the supramolecular organization
30 of LPS and peptidoglycan in membranes, it is possible to work with extracts of biological
31 components of bacterial membranes. Extracts are not realistic from the structural point of
32 view but serve as simple models to study the interaction of peptides with these kinds of
33 molecules. Given the architecture of bacterial membranes, a pertinent question to be asked
34 is: can LPS (Gram-negative bacteria) and peptidoglycan (Gram-positive bacteria) serve as
35 electrostatic barriers that capture AMPs and prevent their interaction with the inner lipid
36 bilayer? Or, on the contrary, these layers saturate and cannot retain excess AMPs, which
37 remain available to permeabilize the inner bilayers? In the end, answering these questions is
38 a matter of concentrations (of AMPs and membrane components) and affinities of AMPs
39 towards the different membrane components.
40
41

42
43 Omiganan, an AMP of clinical relevance [8, 9], was studied for its interaction with
44 peptidoglycan extracts quantitatively. It was observed that there is extensive interaction
45 between the peptide and peptidoglycan. While the results could, at first glance, leave the
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 impression that Gram-positive bacteria cell walls trap AMPs and prevent them from
4 interacting with lipid membranes, in typical efficacy assays the concentration of
5 peptidoglycan is very small and the quantity of peptide need to saturate the bacterial wall is
6 negligible. Both aqueous phase and membrane-bound peptide concentrations are, in practice,
7 the same, in the presence or absence of the wall, defeating its role as peptide trap. Henriques
8 *et al.* [10] used *Limulus* amebocyte lysate to evaluate the binding of the AMP Sub3 to LPS
9 and lipoteichoic acids (LTA). The data was used to propose a model of action of Sub3 in
10 which it targets the outer membrane of bacteria through electrostatic attractions, causing
11 permeation. The interaction with the inner membrane is not lytic: Sub3 translocates the inner
12 membrane to bind to intracellular targets. The 21 kDa peptide based on the N-terminal
13 region of the neutrophil bactericidal/permeability-increasing protein (rBPI₂₁) binds LPS
14 aggregates [11, 12], which was hypothesized to facilitate LPS clearance by macrophage
15 phagocytosis and/or blocking of LPS specific receptor recognition [12]. Later, the same
16 authors confirmed by AFM Force spectroscopy that soluble LPS decrease the interaction of
17 rBPI₂₁ with bacteria, especially *S. aureus* [13].
18
19
20
21
22
23
24
25
26
27
28

29 **BACTERIA IN BIOPHYSICAL STUDIES**

30
31
32
33 Several groups translated biophysical methodologies usually applied in artificial
34 model systems to bacteria to study the molecular events that take place when AMPs interact
35 with bacterial membranes (Table 1). This trend has been growing and important
36 contributions have been published recently. In fact, this trend encompasses the fast
37 development of cell biophysics in general. Whole-cell Nuclear Magnetic Resonance (NMR)
38 [14], AFM [15], single particle tracking microscopies [16], isothermal titration calorimetry
39 [17], zeta-potential light scattering [18] and fluorescence spectroscopy [19] are some
40 examples of biophysical techniques recently applied to study molecular events directly on
41 cells.
42
43
44
45
46
47

48 The specific case of AMPs action in bacteria has been addressed by Alves *et al.* [4]
49 *who* studied *E. coli* morphologic collapse induced by two AMPs by AFM in standard
50 conditions of bacterial growth and density. The collapse of the structure of the cell occurs at
51 an AMP concentration that coincides with the minimum inhibitory concentration, MIC.
52 Moreover, this is concomitant with electroneutralization of bacterial surfaces, as measured
53 by zeta-potential light scattering. This parallels the action of AMP in vesicles, in which
54 membrane coverage and electroneutralization has been quantitatively determined [20]. The
55
56
57
58
59
60

1
2
3 similarities observed between vesicles-based and bacteria-based work, even when precise
4 quantitative reasoning is applied, has led to the proposal that biological action parameters,
5 such as the MIC, can be estimated within reasonable limits from data on lipid affinity
6 obtained in vesicles, namely:
7
8
9

$$MIC = \frac{\sigma}{K_p \gamma_L}$$

10
11
12
13
14
15
16 γ_L is the volumic mass of the lipids, σ is the peptide:lipid ratio on the saturated membrane
17 itself, and K_p is the peptide lipid-aqueous environment partition constant. This thesis is
18 detailed in references [3, 18, 21].
19

20
21 The need for peptides to saturate bacterial membranes and to cause permeabilization
22 and inactivation explains why it is so rare to find AMP with MIC below 1 μM , an intriguing
23 question that upsets peptide drug medicinal chemists. It is hypothesized that AMP with MIC
24 below 1 μM have targets other than the membranes. Some may translocate membranes [22]
25 and reach intracellular targets.
26
27

28
29 Independent studies by other groups corroborated the finding that AMPs act on
30 bacteria under the same general principles as in vesicles. Stella's group has recently
31 demonstrated [7] that the AMP PMAP 23 is active only when bound peptides completely
32 saturate bacterial membranes, which occurs at micromolar total peptide concentration under
33 the experimental conditions used to measure bactericidal activity. Stella *et al.* used steady-
34 state and time-resolved fluorescence spectroscopy. Using a different technique, CD,
35 Romanelli [5], with a completely independent study from the others previously described,
36 also found important similarities between AMPs action in vesicles and bacteria: AMPs
37 change conformation upon binding to membranes. LPS in bacteria are able to induce the
38 conformational changes also observed in lipid bilayer vesicles.
39
40
41
42
43
44
45

46 The question remains on if it is possible for peptides to reach micromolar
47 concentrations *in vivo* in a biological or pharmacological context. However, it is known that
48 human neutrophil peptide 1, HNP-1, for instance, may reach concentrations between 30 μM
49 and nearly 50 μM during infection [23]. For topical administration, reaching concentrations
50 above μM is not a problem but for systemic administration this may be a challenge. Whilst
51 the toxicology of peptides is usually not very stringent, the fast clearance from plasma does
52 not favor high circulating concentration [24]. Chemical modification of peptides to improve
53 pharmacokinetics is possible but it is still a challenge [24, 25].
54
55
56
57
58
59
60

1
2
3 The process of membrane permeabilization by AMPs was studied from the kinetic
4 point of view by Freire *et al.* [26]. The action of an AMP on *E. coli* was assumed to be
5 described by two consecutive steps: cooperative binding to the membrane and
6 permeabilization. An innovative variant of Fluorescence Activated Cell Sorting (FACS),
7 time-resolved FACS, was used in association to the Syto-9/Propidium Iodide “live-dead”
8 assay [27] to follow the kinetic course of membrane permeabilization and allow retrieving
9 the kinetic constant, associated to membrane association and subsequent membrane
10 permeabilization as well as a cooperativity factor. Although the results are in general
11 agreement with AMPs mechanism of action previously proposed based on vesicle work, the
12 results varied among strains meaning that the details of the AMP action, mainly
13 cooperativity, depends on the specific membrane composition. It is worth highlighting that a
14 mutant strain with LPS having very short saccharide moieties are resistant to the AMP. This
15 probably results from low electrostatic attraction of the AMP at the bacterial outer surface
16 and/or abrogation of the conformational changes that trigger membrane permeabilization
17 [5], which prevents the AMP from reaching and perturbing the inner lipid bilayer. This is in
18 agreement with proposals that AMPs may fuse or at least perturb outer and inner membranes
19 of bacteria [12]. Gee *et al.* [6] compared the action of a fluorescently labeled AMP in
20 vesicles and bacteria using time-lapse fluorescence lifetime imaging and assigned the
21 differences to this dynamic interplay between the effects of AMP in inner and outer
22 membranes. A study of Dathe’s group [28] with a cyclic peptide had shown that the LPS in
23 *E. coli* are important for the peptide binding and partition. Absence of bacterial coverage by
24 the AMP abrogates membrane permeabilization. The interaction with the outer membrane
25 modulates the guidance of the AMP to the inner membrane, which is determinant for
26 antimicrobial activity.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 FROM BACTERIA TO TUMOURS

46
47
48 Following the discovery that the surface of cancer cells is rich in anionic lipids, a
49 great deal of effort is being concentrated in developing AMPs as anticancer peptides, ACPs
50 [29]. Very few studies are available on the action of ACPs on tumor cell membranes, some
51 of which are summarized in Table 2. Only a subset of AMPs displays anticancer activity and
52 there is strong controversy on whether AMPs and ACPs act the same way [30]. The outer
53 surfaces of cancer cell membranes are not as anionic as in bacteria. Given the role of
54 electrostatics in the mode of action of AMPs it is legitimate to question if ACPs follow the
55
56
57
58
59
60

1
2
3 mechanism of AMPs to permeabilize membranes. In particular, there were concerns that
4 ACPs could accumulate on the surface of cancer cells to the extent observed in bacteria.
5 Gaspar *et al.* [31] used zeta-potential light scattering spectroscopy with lung carcinoma
6 A549 cells to demonstrate that ACPs SVS-1 is active at stages preceding membrane
7 neutralization, in contrast with AMPs that target membranes. HNP-1 has a plethora of
8 effects on cellular morphology and stiffness, membrane ultrastructure and charge on solid
9 and hematological tumor cells [32]. For HNP-1, AFM and zeta-potential measurements
10 show a preferential binding to solid tumor cells from human prostate adenocarcinoma when
11 compared to human leukemia cells. AFM in particular revealed induction of apoptosis
12 concomitant with cellular membrane defects at very low peptide concentrations.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In bacteria, saturation of outer membranes leads to permeabilization and AMP interaction with the inner membrane (Figure 2). ACPs appear to diverge from the mode of action of most AMP, as they translocate membranes prior to saturation of membranes and reach intracellular targets (Figure 2). In these cases, killing may occur by interaction with intracellular targets. It is worth reminding that AMPs are potential Cell-Penetrating Peptides, CPPs [22]. ACPs seem to result from the combination of antimicrobial and cell-penetrating properties in the same peptide.

CONCLUSION

Despite being only a small number of studies when compared to vesicle-based studies, cell-based biophysical studies on the action of AMPs and ACPs constitute important seminal work with a clear growing trend. Recent data sheds light on the molecular-level detail of the mechanism of action of AMPs and ACPs in cells. The vesicle-cell interdisciplinary gap is finally being bridged. The similarities and dissimilarities between the action of AMPs and ACPs in vesicles and cells are finally being unraveled (Figure 2). This demands power to adapt techniques and methodologies, as well as commitment of biophysicists to accept the challenge of performing solid quantitative work in cells.

ACKNOWLEDGMENTS

M. Castanho thanks EPS for the Zervas Award 2014. Fruitful discussion with Professors Lorenzo Stella and Alessandra Romanelli during the 33rd European Peptide Symposium were inspiring for this paper. Projects Ciência Sem Fronteiras PVE 171/2012 (CAPES, Brazil)

and MSCA-RISE-2014-Nr644167 are acknowledged. D. Gaspar and J. Freire are recipients of fellowships SFRH/BPD/73500/2010 and SFRH/BD/70423/2010 from FCT, Portugal, respectively. A.S. Veiga acknowledges FCT, Portugal, for funding within the FCT Investigator Programme (IF/00803/2012).

REFERENCES

- 1 Drucker, P., Grill, D., Gerke, V., Galla, H.J. Formation and characterization of supported lipid bilayers containing phosphatidylinositol-4,5-bisphosphate and cholesterol as functional surfaces. *Langmuir* 2014. DOI: 10.1021/la503203a.
- 2 Salay, L.C., Procopio, J., Oliveira, E., Nakaie, C.R., Schreier, S. Ion channel-like activity of the antimicrobial peptide tritrypticin in planar lipid bilayers. *FEBS Lett.* 2004; **565**(1-3): 171-175. DOI:10.1016/j.febslet.2004.03.093.
- 3 Melo, M.N., Ferre, R., Castanho, M.A.R.B. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. *Nature Rev.Microbiol.*2009; **7**(3): 245-250. DOI: 10.1038/Nrmicro2095.
- 4 Alves, C.S., Melo, M.N., Franquelim, H.G., Ferre, R., Planas, M., Feliu, L., Bardaji, E., Kowalczyk, W., Andreu, D., Santos, N.C., Fernandes, M.X., Castanho, M.A.R.B. Escherichia coli Cell Surface Perturbation and Disruption Induced by Antimicrobial Peptides BP100 and pepR. *J. Biol.Chem.* 2010; **285**(36): 27536-27544. DOI: 10.1074/jbc.M110.130955.
- 5 Avitabile, C., D'Andrea, L.D., Romanelli, A. Circular Dichroism studies on the interactions of antimicrobial peptides with bacterial cells. *Sci. Rep.* 2014; **4**(4293): 1-7. DOI: 10.1038/srep04293.
- 6 Gee, M.L., Burton, M., Grevis-James, A., Hossain, M.A., McArthur, S., Palombo, E.A., Wade, J.D., Clayton, A.H. Imaging the action of antimicrobial peptides on living bacterial cells. *Sci. Rep.* 2013; **3**(1557): 1-6. DOI: 10.1038/srep01557.
- 7 Roversi, D., Luca, V., Aureli, S., Park, Y., Mangoni, M.L., Stella, L. How Many Antimicrobial Peptide Molecules Kill a Bacterium? The Case of PMAP-23. *ACS Chem. Biol.* 2014; **9**(9): 2003-2007. DOI: 10.1021/Cb500426r.
- 8 Melo, M.N., Castanho, M.A.R.B. Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. *Biochim. Biophys. Acta* 2007; **1768**(5): 1277-1290. DOI: 10.1016/j.bbamem.2007.02.005.
- 9 Melo, M.N., Dugourd, D., Castanho, M.A. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. *Recent Pat. Antiinfect. Drug Discov.* 2006; **1**(2): 201-207.
- 10 Torcato, I.M., Huang, Y.H., Franquelim, H.G., Gaspar, D.D., Craik, D.J., Castanho, M.A.R.B., Henriques, S.T. The Antimicrobial Activity of Sub3 is Dependent on Membrane Binding and Cell-Penetrating Ability. *Chembiochem* 2013; **14**(15): 2013-2022. DOI: 10.1002/cbic.201300274.
- 11 Domingues, M.M., Bianconi, M.L., Barbosa, L.R., Santiago, P.S., Tabak, M., Castanho, M.A., Itri, R., Santos, N.C. rBPI21 interacts with negative membranes endothermically promoting the formation of rigid multilamellar structures. *Biochim. Biophys. Acta* 2013; **1828**(11): 2419-2427. DOI: 10.1016/j.bbamem.2013.06.009.
- 12 Domingues, M.M., Castanho, M.A.R.B., Santos, N.C. rBPI(21) Promotes Lipopolysaccharide Aggregation and Exerts Its Antimicrobial Effects by (Hemi)fusion

- of PG-Containing Membranes. *Plos One* 2009; **4**(12): 1-8. DOI: 10.1371/Journal.Pone.0008385.
- 13 Domingues, M.M., Silva, P.M., Franquelim, H.G., Carvalho, F.A., Castanho, M.A., Santos, N.C. Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria. *Nanomedicine* 2014; **10**(3): 543-551. DOI: 10.1016/j.nano.2013.11.002.
- 14 Lerche, M.H., Jensen, P.R., Karlsson, M., Meier, S. NMR Insights into the Inner Workings of Living Cells. *Anal. Chem.* 2014. DOI: 10.1021/ac501467x.
- 15 Pillet, F., Chopinet, L., Formosa, C., Dague, E. Atomic Force Microscopy and pharmacology: from microbiology to cancerology. *Biochim. Biophys. Acta* 2014; **1840**(3): 1028-1050. DOI: 10.1016/j.bbagen.2013.11.019.
- 16 Persson, F., Barkefors, I., Elf, J. Single molecule methods with applications in living cells. *Curr. Opin. Biotechnol.* 2013; **24**(4): 737-744. DOI: 10.1016/j.copbio.2013.03.013.
- 17 Alves, I.D., Bechara, C., Walrant, A., Zaltsman, Y., Jiao, C.Y., Sagan, S. Relationships between Membrane Binding, Affinity and Cell Internalization Efficacy of a Cell-Penetrating Peptide: Penetratin as a Case Study. *Plos One* 2011; **6**(9): 1-10. DOI: 10.1371/journal.pone.0024096.
- 18 Melo, M.N., Castanho, M.A. The Mechanism of Action of Antimicrobial Peptides: Lipid Vesicles vs. Bacteria. *Front. Immunol.* 2012; **3**(236): 1-4. DOI: 10.3389/fimmu.2012.00236.
- 19 Ye, J., Fox, S.A., Cudic, M., Rezler, E.M., Lauer, J.L., Fields, G.B., Terentis, A.C. Determination of Penetratin Secondary Structure in Live Cells with Raman Microscopy. *J. Am. Chem. Soc.* 2010; **132**(3): 980-988. DOI: 10.1021/Ja9043196.
- 20 Ferre, R., Melo, M.N., Correia, A.D., Feliu, L., Bardaji, E., Planas, M., Castanho, M. Synergistic Effects of the Membrane Actions of Cecropin-Melittin Antimicrobial Hybrid Peptide BP100. *Biophys. J.* 2009; **96**(5): 1815-1827. DOI: 10.1016/j.bpj.2008.11.053.
- 21 Melo, M.N., Ferre, R., Feliu, L., Bardaji, E., Planas, M., Castanho, M.A.R.B. Prediction of Antibacterial Activity from Physicochemical Properties of Antimicrobial Peptides. *Plos One* 2011; **6**(12): 1-6. DOI: 10.1371/journal.pone.0028549.
- 22 Henriques, S.T., Melo, M.N., Castanho, M.A. Cell-penetrating peptides and antimicrobial peptides: how different are they? *Biochem. J.* 2006; **399**(1): 1-7. DOI: 10.1042/BJ20061100.
- 23 Panyutich, A.V., Panyutich, E.A., Krapivin, V.A., Baturevich, E.A., Ganz, T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. *J. Lab. Clin. Med.* 1993; **122**(2): 202-207.
- 24 Sewald, N., Jakubke, H.-D., *Peptides: Chemistry and Biology*, Second, Revised and Updated ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, **2009**.
- 25 Hamman, J.H., Steenekamp, J.H., in *Peptide Drug Discovery and Development*, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, **2011**.
- 26 Freire, J.M., Gaspar, D., de la Torre, B.G., Veiga, A.S., Andreu, D., Castanho, M.A. Monitoring antibacterial permeabilization in real time using time-resolved flow cytometry. *Biochim. Biophys. Acta* 2014; **1848**(2): 554-560. DOI: 10.1016/j.bbamem.2014.11.001.
- 27 Berney, M., Hammes, F., Bosshard, F., Weilenmann, H.U., Egli, T. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight kit in combination with flow cytometry. *Appl. Environ. Microbiol.* 2007; **73**(10): 3283-3290. DOI: 10.1128/Aem.02750-06.

- 1
2
3 28 Junkes, C., Harvey, R.D., Bruce, K.D., Dolling, R., Bagheri, M., Dathe, M. Cyclic antimicrobial R-, W-rich peptides: the role of peptide structure and E. coli outer and inner membranes in activity and the mode of action. *European Biophysics Journal with Biophys. Lett.* 2011; **40**(4): 515-528. DOI: 10.1007/s00249-011-0671-x.
- 4
5
6
7 29 Gaspar, D., Veiga, A.S., Castanho, M.A. From antimicrobial to anticancer peptides. A review. *Front. Microbiol.* 2013; **4**(294): 1-16. DOI: 10.3389/fmicb.2013.00294.
- 8
9
10 30 Hoskin, D.W., Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. *Biochim. Biophys. Acta* 2008; **1778**(2): 357-375. DOI: 10.1016/j.bbamem.2007.11.008.
- 11
12
13 31 Gaspar, D., Veiga, A.S., Sinthuvanich, C., Schneider, J.P., Castanho, M.A. Anticancer peptide SVS-1: efficacy precedes membrane neutralization. *Biochemistry* 2012; **51**(32): 6263-6265. DOI: 10.1021/bi300836r.
- 14
15
16 32 Gaspar, D., Freire, J.M., Pacheco, T.R., Barata, J.T., Castanho, M.A. Apoptotic human neutrophil peptide-1 anti-tumor activity revealed by cellular biomechanics. *Biochim. Biophys. Acta* 2014. DOI: 10.1016/j.bbamcr.2014.11.006.
- 17
18
19 33 Torcato, I.M., Huang, Y.H., Franquelim, H.G., Gaspar, D., Craik, D.J., Castanho, M.A., Troeira Henriques, S. Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. *Biochim. Biophys. Acta* 2013; **1828**(3): 944-955. DOI: 10.1016/j.bbamem.2012.12.002.
- 20
21
22
23
24 34 Schroder-Borm, H., Bakalova, R., Andra, J. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. *FEBS Lett.* 2005; **579**(27): 6128-6134. DOI: 10.1016/j.febslet.2005.09.084.
- 25
26
27
28
29 35 Eliassen, L.T., Berge, G., Leknessund, A., Wikman, M., Lindin, I., Lokke, C., Ponthan, F., Johnsen, J.I., Sveinbjornsson, B., Kogner, P., Flaegstad, T., Rekdal, O. The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. *Int. J. Cancer* 2006; **119**(3): 493-500. DOI: 10.1002/ijc.21886.
- 30
31
32
33
34 36 Lin, W.J., Chien, Y.L., Pan, C.Y., Lin, T.L., Chen, J.Y., Chiu, S.J., Hui, C.F. Epinecidin-1, an antimicrobial peptide from fish (*Epinephelus coioides*) which has an antitumor effect like lytic peptides in human fibrosarcoma cells. *Peptides* 2009; **30**(2): 283-290. DOI: 10.1016/j.peptides.2008.10.007.
- 35
36
37
38
39 37 Wang, K.R., Yan, J.X., Zhang, B.Z., Song, J.J., Jia, P.F., Wang, R. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. *Cancer Lett.* 2009; **278**(1): 65-72. DOI: 10.1016/j.canlet.2008.12.027.
- 40
41
42
43 38 Sinthuvanich, C., Veiga, A.S., Gupta, K., Gaspar, D., Blumenthal, R., Schneider, J.P. Anticancer beta-hairpin peptides: membrane-induced folding triggers activity. *J. Am. Chem. Soc.* 2012; **134**(14): 6210-6217. DOI: 10.1021/ja210569f.
- 44
45
46 39 Paredes-Gamero, E.J., Martins, M.N.C., Cappabianco, F.A.M., Ide, J.S., Miranda, A. Characterization of dual effects induced by antimicrobial peptides: Regulated cell death or membrane disruption. *Biochim. Biophys. Acta* 2012; **1820**(7): 1062-1072. DOI: 10.1016/j.bbagen.2012.02.015.
- 47
48
49
50 40 Kao, F.S., Pan, Y.R., Hsu, R.Q., Chen, H.M. Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell. *Biochim. Biophys. Acta* 2012; **1818**(12): 2927-2935. DOI: 10.1016/j.bbamem.2012.07.019.
- 51
52
53
54 41 Li, J.T., Zhang, J.L., He, H., Ma, Z.L., Nie, Z.K., Wang, Z.Z., Xu, X.G. Apoptosis in human hepatoma HepG2 cells induced by corn peptides and its anti-tumor efficacy in H22 tumor bearing mice. *Food Chem. Toxicol.* 2013; **51**: 297-305. DOI: 10.1016/j.fct.2012.09.038.
- 55
56
57
58
59
60

- 1
2
3 42 Ma, J., Huang, F., Lin, H., Wang, X. Isolation and purification of a peptide from
4 Bullacta exarata and its impact on apoptosis in prostate cancer cells. *Mar. Drugs*
5 2013; **11**(1): 266-273. DOI: 10.3390/md11010266.
- 6 43 Xu, H., Chen, C.X., Hu, J., Zhou, P., Zeng, P., Cao, C.H., Lu, J.R. Dual modes of
7 antitumor action of an amphiphilic peptide A(9)K. *Biomaterials* 2013; **34**(11): 2731-
8 2737. DOI: 10.1016/j.biomaterials.2012.12.039.
- 9 44 de Azevedo, R.A., Figueiredo, C.R., Ferreira, A.K., Matsuo, A.L., Massaoka, M.H.,
10 Girola, N., Auada, A.V., Farias, C.F., Pasqualoto, K.F., Rodrigues, C.P., Barbuto, J.A.,
11 Levy, D., Bydlowski, S.P., de Sa-Junior, P.L., Travassos, L.R., Lebrun, I. Mastoparan
12 induces apoptosis in B16F10-Nex2 melanoma cells via the intrinsic mitochondrial
13 pathway and displays antitumor activity in vivo. *Peptides* 2014. DOI:
14 10.1016/j.peptides.2014.09.024.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Selected recent illustrative papers on the application of biophysical techniques directly in bacteria to study the action of AMP

Technique	AMP	Bacterium	Short description	Ref.
AFM and Zeta-potential Light Scattering	pepR and BP100	<i>E. coli</i>	Zeta-potential measurements of live bacterial cells in the presence of AMP. At MIC, the surface of the cells becomes neutral and the membranes collapse. Quantitative surface roughness analyses were performed.	[4]
FLIM	Fluorescently-labelled melittin derivative K-14 AlexaFluor-430	<i>E. coli</i>	Direct imaging of the action of the lytic action of AMP in living bacterial cells	[6]
AFM	R-BP100 and RW-BP100	<i>E. coli</i> and <i>S. aureus</i>	Antibacterial efficiency follows the affinity for bacterial membrane and is mainly driven by electrostatic interactions.	[33]
AFM, Zeta-potential Light Scattering, flow cytometry, fluorescence spectroscopy, and confocal imaging	Sub3	<i>E. coli</i> and <i>S. aureus</i>	Sub3 targets the anionic outer membrane of Gram-negative bacteria by electrostatic attraction, permeates the outer membrane, and translocates the inner membrane to reach intracellular targets. A similar mechanism is proposed for Gram-positive, with lipoteichoic acids replacing the liposaccharides as electrostatic attractors of AMP	[10]
Steady-state and time-resolved fluorescence spectroscopy	PMAP-23	<i>E. coli</i>	The number of AMP required to kill a bacterium was estimated.	[7]
CD	Magainin 2 and cecropin A	<i>E. coli</i>	Study of AMP conformational changes upon bacterial binding.	[5]
Flow cytometry/ Membrane potential-sensitive dyes; AFM (imaging and force spectroscopy), and Zeta-potential light scattering	rBPI ₂₁	<i>E. coli</i> and <i>S. aureus</i>	Surface perturbation on cells is followed by lysis. rBPI ₂₁ has a binding pocket that may participate on the binding to Gram-negative bacteria.	[13]
Time-resolved FACS	pepR	<i>E. coli</i>	Describes and analyzes the kinetics of bacterial AMP-induced permeabilization. Quantitative kinetic parameters on AMP binding to bacterial membrane, cooperativity and permeabilization are retrieved.	[26]

Table 2 - Selected recent illustrative papers on the application of biophysical techniques directly in tumor cells to study the action of ACP

Technique	ACP	Cell	Short description	Ref.
FACS and Fluorescence Microscopy	NK-2	Human neuroblastoma (NB LA-N-1 and SH-SY5Y); Human colorectal adenocarcinoma (SW480); Human lymphoma (U-937) and Human leukemia (K-562, Jurkat and MOLT-4)	The cytotoxic activity of the peptide was monitored by a Propidium Iodide (PI)-uptake assay.	[34]
FACS, Confocal microscopy and TEM	Lactoferricin B	Human neuroblastoma (Kelly cells, SK-N-DZ and IMR-32)	FACS and microscopy techniques allowed the observation of mitochondrial morphology alterations and mitochondrial membrane potential.	[35]
SEM, and Fluorescence Microscopy	Epinecidin-1	Human fibrosarcoma (HT1080)	Cell death occurred by induced lysis of cell membrane mediated after 48h of treatment by necrosis inhibitory activity.	[36]
FACS, SEM and Confocal fluorescence microscopy	Polybia-MPI	Human leukemia (K562, HL-60, L1210)	The killing mechanism of polybia-MPI AMP involves plasma membrane perturbation. Human cancer cells died after acute injury and bursting in alignment with a necrotic mode of action.	[37]
SEM, TEM And Zeta-potential Light Scattering	SVS-1	Human lung carcinoma (A549), Human epidermal carcinoma (KB), Human breast carcinoma (MCF-7 and MDA-MB-436)	Disruption of cancer cell membrane occurs via pore formation and was monitored with microscopy techniques. Cell membrane surface charge was measured with Zeta-potential and showed that cell death precedes full cell membrane neutralization.	[31, 38]
Confocal microscopy	β -hairpin AMPs (gomesin, protegrin, tachyplesin and polyphemusin II) and their linear analogues	Human erythroleukemia K562 cell	AMP-induced cell death over time was monitored through Ca^{2+} cell levels.	[39]
AFM	CB1a	Human lung carcinoma (NCI-H460 and NCI-H520)	Cancer cell death results mainly from cell surface damage. Cellular biomechanical properties are also affected by the peptide and measured using AFM.	[40]
FACS	Corn peptides	Human hepatocellular	CPs induced S cell-cycle arrest.	[41]

	(CPs)	carcinoma (HepG2)		
FACS, Fluorescence Microscopy	BEPTII and BEPTIII-1	Human prostate adenocarcinoma (PC-3)	The inhibition of PC-3 cellular proliferation and apoptotic death was followed with flow cytometry and fluorescence microscopy analysis.	[42]
SEM, Fluorescence Microscopy	A ₉ K	Human cervical cancer (HeLa) and Human leukemia (HL-60)	Microscopy techniques were used for evaluating peptide's selectivity, entrance and effect on cancer cell membranes.	[43]
FACS, AFM and Zeta-potential Light Scattering	HNP-1	Human prostate adenocarcinoma (PC-3) and Human leukemia (MOLT-4)	Cellular death, morphology, stiffness, and membrane ultrastructure and charge was followed using FACS, AFM and zeta-potential measurements.	[32]
FACS, Fluorescence Microscopy and TEM	Mastoparan	Murine melanoma (B16F10), Human melanoma (A2058), Human cervical carcinoma (SiHa), Human leukemia (Jurkat), Human breast carcinoma (MCF-7, MDA-MB-231, SK-BR-3), Human glioblastoma (U87)	Cell death was evaluated by the loss of mitochondrial membrane potential, chromatin condensation and morphological changes associated with apoptosis.	[44]


FIGURE CAPTIONS

FIGURE 1 - Schematic view of bacterial membranes and their models. Large unilamellar vesicles of lipid bilayers mimic the inner membrane of bacteria both in structure and composition. LPS and peptidoglycan aggregates mimic composition of outer bacterial membranes but not structure, which limits their application to AMP binding studies

FIGURE 2 – Permeabilization of vesicles and bacteria usually demands saturation of membranes. In standard antibacterial activity assays this occurs in or above micromolar concentration ranges. In bacteria, saturation of outer membranes leads to permeabilization and AMP interaction with the inner membrane. Some AMPs are able to translocate membranes at lower concentrations and reach the interior of vesicles or bacteria. In these cases, killing may occur by interaction with intracellular targets. This mechanism is more often associated to ACP.


Question: are the figure original ones or taken from previous manuscripts. In this case were the two figures some how modified? If not you need permission for their use. Moreover the lettering in the figures has to be increased as they are hardly readable and the figures cannot be significantly increased in the text online.

Answer: Both figures are originals and the respective lettering is now increased.



Schematic view of bacterial membranes and their models. Large unilamellar vesicles of lipid bilayers mimic the inner membrane of bacteria both in structure and composition. LPS and peptidoglycan aggregates mimic composition of outer bacterial membranes but not structure, which limits their application to AMP binding studies.

186x182mm (300 x 300 DPI)



Permeabilization of vesicles and bacteria usually demands saturation of membranes. In standard antibacterial activity assays this occurs in or above micromolar concentration ranges. In bacteria, saturation of outer membranes leads to permeabilization and AMP interaction with the inner membrane. Some AMPs are able to translocate membranes at lower concentrations and reach the interior of vesicles or bacteria. In these cases, killing may occur by interaction with intracellular targets. This mechanism is more often associated to ACP.

182x174mm (300 x 300 DPI)

1
2
3 **João Miguel Freire** was born in Constância, Portugal in 1987 and obtained his degree
4 in Biochemistry (University of Lisbon, Portugal) in 2008. After finishing his Master
5 thesis in Biophysics (University of Lisbon, 2010) he is currently pursuing his Ph.D.
6 degree in Biomedicine/Biophysics at Instituto de Medicina Molecular (School of
7 Medicine, University of Lisbon, Portugal). His work is majorly centered on structural
8 viral proteins and membrane-active peptides derived from them. He has been enrolled
9 in understanding Dengue virus infection mechanism; and while studying such process
10 to develop viral protein-based innovative drug candidates. Viruses are very simple
11 biological entities, though very elegant and complex in their nature of living. In addition
12 he has special interest in working on new biophysical methodologies to study and
13 access membrane-active peptides mode-of-action at a molecular level.
14
15

16
17 **Diana Gaspar** was born in Porto, Portugal, in 1982, graduated in Pharmaceutical
18 Sciences (University of Porto, Portugal) in 2006 and in 2010 obtained her Ph.D. degree
19 in Pharmaceutical and Medicinal Chemistry (University of Porto, Portugal). Since 2011
20 she is a postdoctoral researcher at the Institute of Molecular Medicine (IMM, Lisbon,
21 Portugal) where she currently focuses on the study and development of biologically
22 active peptides as new anticancer agents. Additionally, she is interested in the
23 characterization of cell-cell communication in metastatic cancer. Her research
24 combines a wide variety of experimental methodologies from biophysical to imaging
25 techniques.
26
27

28
29 **Ana Salomé Veiga** was born in Lisbon, Portugal, in 1980. She graduated in
30 Biochemistry in 2003 (University of Lisbon, Portugal) and obtained her PhD degree in
31 Biochemistry in 2008 (University of Lisbon, Portugal). From 2009 to 2011 she worked
32 as a postdoctoral researcher at the National Cancer Institute (NIH, USA). Currently she
33 is a researcher at the Instituto de Medicina Molecular, Faculdade de Medicina de
34 Lisboa. Her work is focused on the study of the activity and mechanism of action of
35 antimicrobial and antiviral peptides.
36
37


38
39 **Miguel Castanho** was born in Santarém, Portugal, in 1967. He graduated in
40 Biochemistry (University of Lisbon, Portugal, 1990), has a Ph.D degree in Molecular
41 Biophysics (Technical University of Lisbon, Portugal, 1993) and habilitation in Physical
42 Biochemistry (University of Lisbon, Portugal, 1999). He became a group leader in the
43 Faculty of Sciences at the University of Lisbon, Portugal, where he started working on
44 the mechanism of action of membrane active peptides at the molecular level. M
45 Castanho is now in the Instituto de Medicina Molecular, in the School of Medicine;
46 University of Lisbon. His work includes the development of methodologies aiming at
47 specific functional and structural information, related to cell-penetrating, antimicrobial,
48 anticancer, and viral fusion inhibitor peptides, and neuropeptide drugs. In 2014 Miguel
49 was one of the recipients of the Zervas award of the European Peptide Society
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



João Freire
1150x1310mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Diana Gaspar
781x781mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Ana Salomé Veiga
666x792mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Miguel Castanho
114x138mm (300 x 300 DPI)